These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 24555235

  • 1. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A, Nagy H, Radics P, Tóth A, Tamás G.
    Ideggyogy Sz; 2013 Nov 30; 66(11-12):365-71. PubMed ID: 24555235
    [Abstract] [Full Text] [Related]

  • 2. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 3. [Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
    Nagy H, Takáts A, Tóth A, Bereczki D, Klivényi P, Dézsi L, Dibó G, Vécsei L, Kovács N, Aschermann Z, Komoly S, Varannai L, Zemlényi G, Valikovics A.
    Ideggyogy Sz; 2014 Nov 30; 67(11-12):385-9. PubMed ID: 25720240
    [Abstract] [Full Text] [Related]

  • 4. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A, Nagy H, Wacha J, Bereczki D, Takáts A.
    Neuropsychopharmacol Hung; 2015 Dec 30; 17(4):191-6. PubMed ID: 26727723
    [Abstract] [Full Text] [Related]

  • 5. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
    Ludin HP, Surber Ch.
    Praxis (Bern 1994); 2006 Dec 20; 95(51-52):2013-8. PubMed ID: 17294589
    [Abstract] [Full Text] [Related]

  • 6. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2009 Dec 20; 165(8-9):718-27. PubMed ID: 19150100
    [Abstract] [Full Text] [Related]

  • 7. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
    Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, Chacón J, García-Ruiz PJ, Lezcano E, Mir P, Martinez-Castrillo JC, Martínez-Torres I, Puente V, Sesar A, Valldeoriola-Serra F, Yañez R.
    Neurologia; 2013 Dec 20; 28(9):558-83. PubMed ID: 23880230
    [Abstract] [Full Text] [Related]

  • 8. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M, Rizzone M, Merola A, Angrisano S, Rizzi L, Montanaro E, Cicolin A, Lopiano L.
    Acta Neurol Scand; 2013 May 20; 127(5):e28-32. PubMed ID: 23311399
    [Abstract] [Full Text] [Related]

  • 9. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
    Titova NV, Katunina EA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015 May 20; 115(3):94-100. PubMed ID: 26171484
    [Abstract] [Full Text] [Related]

  • 10. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 11. [Current treatment strategies for Parkinson's disease].
    Südmeyer M, Wojtecki L, Schnitzler A.
    Fortschr Neurol Psychiatr; 2011 Dec 15; 79(12):733-43. PubMed ID: 22161168
    [No Abstract] [Full Text] [Related]

  • 12. Medical treatment of Parkinson's disease.
    Ahlskog JE.
    Compr Ther; 1989 Mar 15; 15(3):53-9. PubMed ID: 2650977
    [No Abstract] [Full Text] [Related]

  • 13. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
    Worth PF.
    Pract Neurol; 2013 Jun 15; 13(3):140-52. PubMed ID: 23487815
    [Abstract] [Full Text] [Related]

  • 14. [Selection of the optimal device-aided therapy in Parkinson's disease].
    Kovács N, Aschermann Z, Juhász A, Harmat M, Pintér D, Janszky J.
    Ideggyogy Sz; 2019 Jan 30; 72(1-2):5-11. PubMed ID: 30785241
    [Abstract] [Full Text] [Related]

  • 15. [Clinical studies with levodopa/carbidopa intestinal gel].
    Klivényi P, Vécsei L.
    Ideggyogy Sz; 2014 Jan 30; 67(1-2):5-8. PubMed ID: 24654442
    [Abstract] [Full Text] [Related]

  • 16. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I, Benita V, Del Álamo de Pedro M, Ley L, Martinez Castrillo JC.
    Clin Neuropharmacol; 2017 Jan 30; 40(3):103-107. PubMed ID: 28452905
    [Abstract] [Full Text] [Related]

  • 17. What to do when Sinemet fails: Part one.
    Klawans HL.
    Clin Neuropharmacol; 1984 Jan 30; 7(2):121-33. PubMed ID: 6733692
    [No Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B.
    J Med Econ; 2019 Mar 30; 22(3):215-225. PubMed ID: 30484353
    [Abstract] [Full Text] [Related]

  • 19. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA.
    Mov Disord; 2016 Apr 30; 31(4):530-7. PubMed ID: 26817533
    [Abstract] [Full Text] [Related]

  • 20. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B, Pihlstrøm L, Aasly J, Tysnes OB, Egge A, Dietrichs E.
    Tidsskr Nor Laegeforen; 2017 May 30; 137(9):619-623. PubMed ID: 28468476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.